Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement

Vascular Medicine

Volumn 6, Issue 1, 2001, Pages 23-29

  Bell, Gregory K ^a   Goldhaber, Samuel Z ^b,c  

^a CHARLES RIVER ASSOCIATES   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cost; Hip replacement; Knee replacement; Low molecular weight heparin; Prophylaxis; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ARDEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; BLEEDING; BLOOD PRESSURE MONITORING; BOLUS INJECTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COST UTILITY ANALYSIS; DEEP VEIN THROMBOSIS; DRUG COST; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LONG TERM CARE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; PATIENT CODING; PRIORITY JOURNAL; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; SHORT COURSE THERAPY; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT;

ADULT; AGED; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; CHI-SQUARE DISTRIBUTION; COST-BENEFIT ANALYSIS; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PULMONARY EMBOLISM; RETROSPECTIVE STUDIES; VENOUS THROMBOSIS; WARFARIN;

EID: 0035031261     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1191/135886301670156965     Document Type: Article

References (30)

1. NIH consensus conference on prevention of venous thrombosis and pulmonary embolism. JAMA 1986; 256: 744-49.
2. Amstutz HC, Friscia DA, Dorey F, Carney BT. Warfarin prophylaxis to prevent mortality from pulmonary embolism after total hip replacement. J Bone Joint Surg Am 1989; 71A: 321-26.
3. Mohr DN, Silverstein MD, Ilstrup DM, Heit JA, Morrey BF. Venous thromboembolism associated with hip and knee arthroplasty: current prophylactic practices and outcomes. Mayo Clin Proc 1992; 67: 861-70.
4. Anderson FA, Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A, Patwardhan NA. Physician practices in the prevention of venous thromboembolism. Ann Intern Med 1991; 115: 591-95.
5. Grossman RS. Changing patterns of prophylaxis for deep venous thrombosis following elective hip replacement. Orthopedics 1993; 16: 19-22.
6. Anderson DR, O'Brien BJ, Levine MN, Roberts R, Wells PS, Hirsh J. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med 1993; 119: 1105-12.
7. Bergqvist D, Matzsch T, Jendteg S, Lindgren B, Persson U. The cost-effectiveness of prevention of post-operative thromboembolism. Acta Chir Scand Suppl 1990; 556: 36-41.
8. Hauch O, Khattar SC, Jorgensen LN. Cost-benefit analysis of prophylaxis against deep vein thrombosis in surgery. Semin Thromb Hemost 1991; 17 (suppl 3): 280-83.
9. Hull RD, Hirsh J, Sackett DL, Stoddart GL. Cost-effectiveness of primary and secondary prevention of fatal pulmonary embolism in high risk surgical patients. Can Med Assoc J 1982; 127: 990-95.
10. Oster G, Tuden RL, Colditz GA. A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery. JAMA 1987; 257: 203-208.
11. Paiement GD, Wessinger SJ, Harris WH. Cost-effectiveness of prophylaxis in total hip replacement. Am J Surg 1991; 161: 519-24.
12. Menzin J, Richner R, Huse D, Colditz GA, Oster G. Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmacoeconomic evaluation. Ann Pharmacother 1994; 28: 271-75.
13. Salzman EW, Davies GC. Prophylaxis of venous thromboembolism: analysis of cost effectiveness. Ann Surg 1980; 191: 207-18.
14. Hyers TM, Hull RD, Weg J. Antithrombotic therapy for venous thromboembolic disease. Chest 1989; 95: 37S.
15. Drug facts and comparisons. St Louis, MO: Facts and Comparisons, Inc., 1994.
16. RD Heparin Arthroplasty Group. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. J Bone Joint Surg Am 1994; 76: 1174-85.
17. Leclerc JR, Geerts WH, Desjardins L et al. Prevention of deep vein thrombosis after major knee surgery - a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost 1992; 67: 417-23.
18. Levine MN, Hirsh J, Gent M et al. Prevention of deep vein thrombosis after elective hip surgery: a randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991; 114: 545-51.
19. Turpie AG, Levine MN, Hirsh J et al. A randomized controlled trial of a low molecular weight heparin (enoxaparin) to prevent deep vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315: 925-29.
20. Hock JA, Nurmohamed MT, Hamelynck KJ et al. Prevention of deep vein thrombosis (DVT) following total hip replacement by a low molecular weight heparinoid (ORG 10172). Thromb Haemost 1992; 67: 28-32.
21. Nurmohamed MT, Rosendaal FR, Buller HR et al. Low molecular weight heparin versus standard heparin in general and orthopaedic surgery: a meta analysis. Lancet 1992; 340: 152-56.
22. Hull RD, Raskob GE, Gent M et al. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. JAMA 1990; 263: 2313-17.
23. Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994; 271: 1780-85.
24. Levine MN, Hirsh J. Hemorrhagic complications of anticoagulant therapy. Semin Thromb Hemost 1986; 12: 39-57.
25. Redbook 1993. Montvale, NJ: Medical Economics Data, Inc., 1993.
26. Hull R, Raskob G, Pineo G et al. A comparison of subcutaneous low molecular weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993; 329: 1370-76.
27. Brenkel IJ, Clancy MJ. Total hip replacement and antithrombotic prophylaxis. Br J Hosp Med 1989; 42: 282-84.
28. Wittmann PH, Wittmann FW, Ring PA. Venous thromboembolic disease in uncemented total hip replacement surgery - a one-year follow-up of 490 patients. J R Soc Med 1991; 84: 536-39.
29. Andersen M, Wille-Jorgensen P. Late complications of asymptomatic deep venous thrombosis. Eur J Surg 1991; 157: 527-30.
30. Francis CW, Ricotta JJ, Evarts CM, Marder VJ. Long-term clinical observations and venous functional abnormalities after asymptomatic venous thrombosis following total hip or knee arthroplasty. Clin Orthop 1988; 232: 271-78.